Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce Injection and Intravesical Instillation in Subjects with Urothelial Carcinoma
Sponsor: |
NanOlogy, LLC |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS3837 |
U.S. Govt. ID: |
NCT03636256 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder by catheter) right after the injection. The purpose of this study is to find the dose which is tolerated the best, gives the least side effects when injected directly into the resected bladder and instilled in the bladder, and to find out which dose may kill cancer cells.
This study is closed
Investigator
Joel DeCastro, MD, MPH
Are you at least 18 years old? |
Yes |
No |
Do you have metatstatic invasive bladder cancer (MIBC)? |
Yes |
No |
Are you able to perform everyday activities independently? |
Yes |
No |